FDA defends Aduhelm's accelerated approval, while others call for reform
Regulatory NewsJeff CravenAdvertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesClinical TrialsEthicsHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy